Safety and efficacy of Nordic walking training in adult patients with asthma: a pilot randomised controlled trial with a mixed-methods approach

Abstract

[Abstract] Introduction. Nordic walking (NW) may benefit patients with asthma by enhancing functional exercise capacity and reducing symptoms, though evidence remains limited. This study assessed NW safety and effects in patients with asthma and explored their experiences.

Methods. A mixed-method two-arm, parallel, pilot randomised controlled trial was conducted in A Coruña between (July 2021 - May 2025). Adults with asthma attended three educational sessions before randomization to NW group (NWG) or control group (CG). The NWG performed NW 3 days/week, during eight weeks, at 70-85% of maximum heart rate. Both groups maintained usual care. The primary outcome was the 6-min walking distance (6MWD). Secondary outcomes included 1-min Sit-to-Stand Test, physical activity (PA) and adverse events. Experiences were explored through individual interviews.

Results. Thirty-four participants with asthma (mean ± SD age 45.4 ± 11.4 years, 82.4% female) were randomly allocated to NWG (n = 17) or CG (n = 17). NW adherence was 80.1 + 16.1%. No adverse effects occurred. Post-intervention, the NWG increased 6MWD by 12.1 ± 30.4 m (m) (P = .119), whereas the CG decreased by 13.6 ± 41.3m (P = .193), without significant between-groups differences (P = .067; Cohen's d = 0.7; 95% confidence interval (CI) 0.-1.3). The NWG spent more time in vigorous PA compared to CG (P = .016, r = 0.4, 95% CI 0.8-52.4). All NWG participants recommended NW, citing health improvements and finding it manageable, comfortable, and implementable.

Conclusion. Although between-groups differences were not significant, NW was safe, feasible, accessible and perceived as beneficial by individuals with asthma. Given the demonstrated safety, future studies should tailor NW intensity to fitness and asthma control levels.